321 results about "Lupus erythematosus" patented technology

The invention provides a Chinese herbal preparation for treating posirasis, which adopts 58 raw medicinal materials such as astragalus root, suberect spatholobus stem, Job stears, glabrous greenbrierrhizome, spreading hedyotis herb, barbed skullcap herb, motherwort herb and the like to manufacture oral agent and abrasive cleaner. The manufacturing method of the invention is as follows: 1. manufacturing by using the above raw material medicines into water-decocted liquid according to the conventional method; 2. manufacturing by using the water-decocted liquid which is manufactured in step 1 into oral liquid according to the conventional method; 3. drying, grinding and sieving the water-decocted liquid which is manufactured in step 1, and taking the throughs as powder; and 4. manufacturinginto powder tablets, granular formulation, medicinal granules or capsules by utilizing step 3 according to the conventional method. The powder and the abrasive cleaner can be manufactured by the following steps: 1. grinding the above raw material medicines; 2. sieving; and 3. taking the throughs, disinfecting and sterilizing to obtain the powder. The invention has high cure rate, low recurrence rate, can treat the primary and the secondary aspects at the same time, is safe and reliable, and can strengthen the autoimmunity. The invention mainly treats various types of posirasis, can treat neurodermatitis, comedo, acne and eczema concurrently, and has effects on lupus erythematosus, syphilis, lepra and skin cancer.

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

The invention relates to a gel composition containing tacrolimus, which contains the tacrolimus and ingredients of a matrix, wherein, the ingredients of the matrix contain one or more of liquid polyethylene glycol, glycerin and propylene glycol, the content of the tacrolimus in the gel is 0.01 percent to 0.5 percent, and the weight ratio of the tacrolimus to one or more of the liquid polyethylene glycol, the glycerin and the propylene glycol is 1: (50 to 3000). The invention further relates to a preparation method of the gel composition of the tacrolimus and the application of the gel composition in the preparation of drugs for the treatment of atopic dermatitis, vitiligo, psoriasis, hormone-dependent dermatitis, intractable neurodermatitis, lupus erythematosus, alopecia areata and other diseases.

The invention relates to a method of treating lupus erythematosus. In one embodiment, the method comprises the step of administering to a patient suffering from lupus erythematosus an effective amount of a composition comprising a conjugate or complex of the general formula

L-X

where the group L comprises a ligand capable of binding to activated macrophages or other stimulated immune cells, and the group X comprises an immunogen, a cytotoxin, or another compound capable of altering macrophage function. In another embodiment, the method comprises the step of administering to a patient suffering from lupus erythematosus an effective amount of a composition comprising a conjugate of the general formula

L-X

where the group L comprises a vitamin, or a vitamin-receptor binding analog or derivative thereof, and the group X comprises an immunogen, a cytotoxin, or another compound capable of altering macrophage function.

This invention discloses functional humanized antibody against CD20 molecules and its application. The functional humanized antibody specifies human CD20 molecules, and is composed of a light chain and a heavy chain, each of which comprises a constant region and a variable region. The constant region of the heavy chain is isotypic human IgG1 constant region, and that of the light chain is isotypic human kappa constant region. The variable region of the heavy chain is shown in SEQ ID No.2, and that of the light chain is shown in SEQ ID No.1. The functional humanized antibody has low immunogenicity. Experiments show that the functional humanized antibody has the same specificity and affinity as the original murine antibody. Drugs containing the functional humanized antibody and its derivatives can be used for treating cancers or immune system diseases with the high-expression of CD20, such as rheumatic arthritis and lupus erythematosus.

The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

The invention discloses a single-chain antibody of human source anti-alexin C3d molecules. A light chain and a heavy chain of the antibody have a unique CDR region; excellent antigen binding activityis realized; the affinity constant reaches 1.22*10<-7> mol/L. Biological distribution experiments prove that the anti-C3d single-chain antibody provided by the invention can be highly gathered in thearthritis positions after entering a mouse model with rheumatoid arthritis; the arthritis serious degree of the three ScFv treatment groups is obviously lower than that of a PBS group; the healing degree has the obvious dose dependency relationship; the result shows that the excellent anti-adhesion/ anti-inflammatory targeted inhibition effects are achieved. In the treatment process on MRL/lpr mice with lupus erythematosus, the anti-C3d single-chain antibody provided by the invention can obviously improve the survival rate of the mice; the symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis and crescent/necrosis and the like in the treatment group are obviously relieved. The result shows that the anti C3d single-chain antibody provided by the invention has excellent application prospects in the preparation of medicine for treating autoimmune diseases.

This invention relates to one anti-extracting nuclear antigen spectrum array to ELISA test agent case for selecting for systematic lupus erythematosus, mixed connective tissue disease, Sjogren syndrome, systemic scleroderma, polymyositis and atrophic arthritis system self immune property antigen ENA spectrum micro array to enzyme immune agent case.

The invention relates to a diclofenac sodium hydrogel microballoon with pH sensitivity, a preparation method and application thereof. In the invention, chitosan and sodium alginate are used as drug carriers to prepare a diclofenac sodium hydrogel microballoon slow release preparation; the mass ratio of a used diclofenac sodium drug to the chitosan to the sodium alginate is (1-3):(5-8):(5-8); and the chitosan is N-succinyl-chitosan. The microballoon preparation can durably develop the drug effect to ensure that diclofenac sodium can be regularly and quantitatively released for a long time; after the microballoon preparation is taken, the blood concentration is stable, the fluctuation is small, and the duration time is long; the microballoon preparation has pH sensitivity, thereby irritations and toxic hazards to the stomach mucous membrane, which are caused by directly and orally taking diclofenac sodium tablets, are reduced; and the microballoon preparation has good effects of cooling down and easing pains and is suitable for various rheumatisms, rheumatoid arthritis, lupus erythematosus, ankylosing spondylitis, various pains caused after operations, fevers caused by various reasons, and the like.

The present invention relates generally to the use of vitamin B12 (cobalamin or cyanocobalamin) alone or in combination with other photoprotective agents, including specifically other vitamins such as vitamin B9 (folic acid or folate) and vitamin B3 (niacin or niacinamide), or any chemical derivative of these vitamins and their salts, as a filter to protect cells against the damaging effects of ultraviolet (UV) light. The invention is, in one aspect, a method of reducing the rate of UV damage to cells exposed to a UV light source, by treating the cells with the vitamin composition, either alone or in combination with other photoprotective agents. Other aspects of the invention are compositions comprising effective amounts of vitamin B12 alone or in combination with other photoprotective agents including vitamin B9 and vitamin B3 and a pharmaceutically-acceptable carrier, that are useful in protecting cells, particularly skin cells, against the burning, genotoxic (mutagenic and carcinogenic), immunosuppressive and photoaging effects of UV light, especially sunlight. The invention has application as a UV light filter in oral preparations including tablets and drinks, topical creams, lotions, sprays, wipes and cosmetics. The invention also has application as a medicinal treatment for dermatological conditions caused by exposure to sunlight, such as actinic keratoses, photodermatitis, photo-induced (discoid) lupus erythematosus and the photosensitizing effects of a variety of drugs used commonly in clinical practice (e.g. certain antihistamines, ACE inhibitors, and antibiotics such as tetracycline).

The invention discloses a methylated marker IL-2RG in a systemic lupus erythematosus (SLE) whole blood genome and application thereof. The sequence of the marker is shown as SEQ ID NO:1. The methylated marker IL-2RG in the SLE whole blood genome is applied to the preparation of a reagent for diagnosing SLE, in particular to a kit for diagnosing SLE. By detecting the methylation level of the methylated marker IL-2RG, a specific methylation locus with a great meaning and a remarkable difference is counted and taken as a basis for early diagnosis of SLE. By adopting the methylated marker, an accurate, cheap and quick clinical tool for early diagnosis of SLE, the disease activity, the curative effect and the prognostic evaluation is provided.

The invention discloses a humic acid active component and a preparation method, application and pharmaceutical composition thereof. The humic acid active component is obtained by biodegradation of natural humic acid, or by selection of plant materials and enrichment through a biochemical humic acid technology. The humic acid active component disclosed by the invention has the efficacies of arresting bleeding, promoting blood circulation, resisting inflammation, resisting rheumatism and removing blood stasis, can be used for preventing or treating lupus erythematosus, and has better effects on arresting bleeding and promoting blood circulation compared with that of Yunnan Baiyao and common humic acid.

The present invention relates to a Chinese medicine composition, and especially a kind of Chinese medicine composition for treating lupus erythematosus, systemic scieroderm, dermatomyositis, panniculitis, behcets disease and connective tissue disease and its preparation process. The Chinese medicine composition is preferably prepared into dripping pill and soft capsule.

The invention discloses lupus erythematosus detection protein chip and kit thereof. The chip comprises a substrate, protein markers distributed in an array type and control point coatings, wherein the markers and the control point coatings are seven antigen markers, positive controls and negative controls comprising dsDNA (double-stranded deoxyribonucleic acid), ssDNA (single stranded deoxyribonucleic acid), Histon, SS-A(Ro60), SS-B(La), Sm (smith) and RNP (ribonucleoprotein)/Sm which are uniformly distributed on the substrate in a dot matrix mode. The invention has comprehensive and appropriate detection indexes and consistent applied reaction conditions, can detect a plurality of indexes at a time, is convenient and quick, greatly improves the detection efficiency and reduces the detection cost. The invention can be suitable for aided diagnosis of suspected lupus erythematosus disease people.

The invention relates to an antrodia camphorate cyclohexanedione compound used for treating autoimmune diseases and a medical composition thereof. The antrodia camphorate cyclohexanedione compound is about 4-hydroxyl-2, 3-dimethoxy-6-methyl-5(3, 7, 11-trimethyl-2, 6, 10-dodecatrien)-2-cyclohexanedione which is separated from antrodia camphorate extract and can relieve systemic erythromelalgia lupus and other symptoms caused by autoimmune diseases. Antrodia camphorate cyclohexanedione in the invention can reduce the content of urine protein of the mammalians with systemic erythromelalgia lupus and the thickness of the antinuclear antibody in blood, relieves kidney inflammation and lesion, lowers the harm of antinuclear antibody on autogenous tissues, and achieves the effect of treating autoimmune diseases such as systemic erythromelalgia lupus, and the like, and the diseases related to kidney by using natural materials without side effects.

The invention relates to an amino methanol derivant and a salt compound thereof as well as a synthesizing method and medical application thereof, belonging to the field of medicines. The medical application is applied in preparing immunosuppressive drugs and drugs for treating transplant rejection, immune and inflammatory diseases, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. The amino methanol derivant and a physiological salt thereof only act on S1P1, downwards regulate the S1P1 expression and suppress lymphocytes from entering peripheral blood circulation.

Methods for the detection of active lupus nephritis (LN) and worsening renal disease activity and/or active LN in patients diagnosed with systemic lupus erythematosus, using a panel of biomarkers including transferrin (Tf), ceruloplasmin (Cp), alpha-1-acid glycoprotein (AGP1), lipocalin-like prostaglandin D synthetase (L-PGDS), and urinary neutrophil gelatinase associated lipocalin (UNGAL).

An alkannin derivative as immuno-suppressive agent and its metallic complex compound with a chemical constitution formulas III and IV disclosed in the specification, wherein in formula III, R is C1-6 saturated, unsaturated and aromatic acyl, in formula IV, R is hydrogen, C1-6 saturated, unsaturated and aromatic acyl, M is metallic Cu, Ca, Zn. The present invention realizes immunological suppression effect, thus can be used for treating diseases relating to human body autoimmune including chronic infectious arthritis, scleredema, lupus erythematosus, HIV infection and malignant tumor.

The present invention generally provides methods for the site-specific modification of peptides, polypeptides, and proteins, e.g., granulocyte macrophage colony-stimulating factor, human superoxide dismutase, annexin, leptin, antibodies and the like, cytokines and chemokines, at their N-termini and at sites at which unnatural aminoacids have been introduced along the protein framework. The modifications described herein can be used for the synthesis and application of the adducts in radio-labeling, molecular imaging and protein therapeutic applications, and the treatment of disorders such as rheumatoid arthritis, lupus erythematosus, psoriasis, multiple sclerosis, type-1 diabetes, Crohn's disease, and systemic sclerosis, Alzheimer disease, cancer, liver disease (e.g., alcoholic liver disease), and cachexia.

The invention discloses a dihydroartemisinin diploid derivative, and a medicine composition and application thereof. The derivative is artemisinin diploid, and is applied to a medicine for treating or preventing malaria caused by plasmodium, a medicine for treating autoimmune diseases such as lupus erythematosus, and an antitumor medicine; the medicine composition is prepared from the dihydroartemisinin diploid derivative and a pharmaceutically acceptable carrier.

The invention discloses a cycloalkane thiophthene derivative and pharmaceutically acceptable salts, metabolic products or prodrugs thereof. A compound can be used for treating diseases related with STAT3 (Signal Transducer and Activator of Transcription 3) activation, such as ovarian cancer, endometrial cancer, cervical cancer, breast cancer, colon cancer, pancreatic cancer, lung cancer, brain cancer, prostate cancer, kidney cancer, liver cancer, bladder cancer, oral cancer, sarcoma, prostate cancer, head and neck squamous cell carcinoma, neuroglioma, melanoma, lymphoma, leukemia, and renal fibrosis, pulmonary fibrosis, rheumatoid arthritis, hair growth, arthritis, psoriasis, lupus erythematosus, inflammatory lung diseases and inflammatory bowel diseases. (The formula is shown in the description.).